2025-05-26-Jefferies-艺康集团（ECL）_全球生物生产炉边谈话系列——艺康全球生命科学_11页_214kb

Equity Research Summary: Ecolab (ECL)

Overview

• Rating: Buy
• Price Target: $310 (implies 19% upside from current price)
• Market Cap: $74.9B (as of 2025)

Life Sciences Segment

• Represents ~4.6% of 2025E sales and ~3.8% of profits.
• Acquired Purolite in 2021 to focus on purification resins, catalysts, etc., used in vaccines and monoclonal antibodies.
• Expected to grow 200-300bps faster than the broader company over the next 5 years.
• Margins >20% by 2030, implying a 12%-15% profit CAGR.

Investment Thesis & Growth Drivers

• Upside driven by: penetration in emerging markets, market share gains, cost savings, disciplined pricing, and effective M&A.
• Focus on: Industrial productivity, SG&A leverage via IoT and digital, differentiation through contamination control and regulatory compliance.
• Risk/Reward considerations: Europe and Asia demand trends, sluggish macro in North America, potential margin compression from raw material costs.

Financial Highlights (Projected)

• Revenue: Expected to grow steadily, with 2026E reaching $17,386 MM from $15,961 MM in 2024, up 2%.
• EPS: Projected to increase from $7.49 in 2024 to $9.73 in 2027, representing a 16% average annual growth over the period.
• EBITDA: Expected to rise from $3,818 MM to $4,530 MM by 2027.
• Long-term growth outlook: Base case 11-15% EPS growth coupled with rapid digital platform expansion.

Sustainability & ESG

• Core competencies: Water & Wastewater Management (from history), Energy Management, Business Model Resilience (B2B services leveraging chemistries).
• Long-term goals: 100% renewable energy by 2030, reduce carbon emissions by 50%, reduce water impact by 40%.
• Enhanced risk management to address ecological impact.

Analyst Certification & Warnings

• All views reflect personal opinions based on robust analysis.
• Key risks: Dilutive M&A, competitive dynamics, regulatory shifts, supply chain disruption, raw material pressures, and achievement of price targets.